Patents by Inventor Bifeng Liu

Bifeng Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230241614
    Abstract: A droplet microfluidic chip and a method for producing microdroplets are disclosed. The droplet microfluidic chip includes at least one droplet-producing unit. The droplet-producing unit includes a dispersion phase chamber, a quantitation chamber, a capillary nozzle, and a continuous phase chamber. The droplet microfluidic chip has a rotation center. The dispersion phase chamber is provided with a loading hole configured to introduce a dispersion phase liquid. The quantitation chamber is in communication with the dispersion phase chamber and further away from the rotation center than the dispersion phase chamber. The capillary nozzle is further away from the rotation center than the quantitation chamber. One end of the capillary nozzle is in communication with the quantitation chamber, and the capillary nozzle is extended from the joining end in a direction away from the rotation center.
    Type: Application
    Filed: August 3, 2021
    Publication date: August 3, 2023
    Inventors: Shunji LI, Xiaoyu CHENG, Bifeng LIU, Chungen QIAN, Kunhui HU
  • Patent number: 10517862
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 31, 2019
    Assignees: NHWA PHARMA. CORPORATION, WUHAN JIAYU TECHNOLOGY CO., LTD.
    Inventors: Guisen Zhang, Xudong Cao, Yin Chen, Yifang Zhang, Minquan Yu, Yinli Qiu, Xiangqing Xu, Tan Zhang, Bifeng Liu, Xin Liu
  • Publication number: 20180318286
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 8, 2018
    Inventors: Guisen Zhang, Xudong Cao, Yin Chen, Yifang Zhang, Minquan Yu, Yinli Qiu, Xiangqing Xu, Tan Zhang, Bifeng Liu, Xin Liu
  • Patent number: 9315496
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: April 19, 2016
    Assignees: HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY, NHWA PHARMA CORPORATION
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xin Liu, Song Zhao, Shicheng Liu, Minquan Yu, Heng Zhang, Xinghua Liu
  • Patent number: 9018213
    Abstract: Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: April 28, 2015
    Assignees: Huazhong University of Science & Technology, NHWA Pharma. Corporation
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Xin Liu, Song Zhao, Bifeng Liu, Minquan Yu, Yinli Qiu
  • Patent number: 8993575
    Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.
    Type: Grant
    Filed: April 1, 2012
    Date of Patent: March 31, 2015
    Assignees: Huazhong University of Science & Technology, NHWA Pharma Corporation
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xiaojun Feng, Song Zhao, Shicheng Liu, Minquan Yu, Yu Lan, Yinli Qiu
  • Publication number: 20140171442
    Abstract: Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.
    Type: Application
    Filed: July 31, 2012
    Publication date: June 19, 2014
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Xin Liu, Song Zhao, Bifeng Liu, Miquan Yu, Yinli Qiu
  • Publication number: 20140113911
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.
    Type: Application
    Filed: April 6, 2012
    Publication date: April 24, 2014
    Applicant: NHWA PHARMA CORPORATION
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xin Liu, Song Zhao, Shicheng Liu, Minquan Yu, Heng Zhang, Xinghua Liu
  • Publication number: 20140024656
    Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.
    Type: Application
    Filed: April 1, 2012
    Publication date: January 23, 2014
    Applicant: HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY NHWA PHARMA CORPORATION
    Inventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xiaojun Feng, Song Zhao, Shicheng Liu, Minquan Yu, Yu Lan, Yinli Qiu